Compare FSM & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSM | IDYA |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | Canada | United States |
| Employees | 1633 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 2005 | 2019 |
| Metric | FSM | IDYA |
|---|---|---|
| Price | $10.27 | $32.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 16 |
| Target Price | $14.00 | ★ $51.21 |
| AVG Volume (30 Days) | ★ 7.4M | 765.5K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $218,710,000.00 |
| Revenue This Year | $35.58 | N/A |
| Revenue Next Year | N/A | $191.08 |
| P/E Ratio | $14.10 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $5.13 | $13.45 |
| 52 Week High | $13.85 | $39.28 |
| Indicator | FSM | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 50.54 |
| Support Level | $9.58 | $29.29 |
| Resistance Level | $11.54 | $34.86 |
| Average True Range (ATR) | 0.54 | 1.56 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 82.82 | 55.66 |
Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'voire, Mexico, and Peru. The company's segment consists of Mansfield, Sango, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d' Ivoire location.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.